Quality of Medicines Commonly Used in the Treatment of Soil Transmitted Helminths and Giardia in Ethiopia: A Nationwide Survey

PLoS Neglected Tropical Diseases

Volumn 8, Issue 12, 2014, Pages

  Suleman, Sultan ^a,b   Zeleke, Gemechu ^a   Deti, Habtewold ^a   Mekonnen, Zeleke ^a,b   Duchateau, Luc ^b   Levecke, Bruno ^b   Vercruysse, Jozef ^b   D'Hondt, Matthias ^b   Wynendaele, Evelien ^b   De Spiegeleer, Bart ^b  

^a JIMMA UNIVERSITY   (Ethiopia)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIPROTOZOAL AGENT; MEBENDAZOLE; TINIDAZOLE; SOIL;

ARTICLE; CONTROLLED STUDY; DOSAGE UNIFORMITY; DRUG QUALITY; DRUG SOLUBILITY; ETHIOPIA; GIARDIA; GIARDIASIS; HEALTH CARE DELIVERY; HELMINTH; HELMINTHIASIS; HUMAN; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PUBLIC HEALTH; QUALITY CONTROL; TABLET DISINTEGRATION; TABLET FRIABILITY; ANIMAL; EPIDEMIOLOGY; PARASITOLOGY; PREVALENCE; QUESTIONNAIRE; SOIL; STANDARDS;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ETHIOPIA; GIARDIASIS; HELMINTHIASIS; HUMANS; MEBENDAZOLE; PREVALENCE; SOIL; SURVEYS AND QUESTIONNAIRES; TINIDAZOLE;

EID: 84928229185     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003345     Document Type: Article

References (67)

1. Coulibaly JT, Fürst T, Silué KD, Knopp S, Hauri D, et al. (2012) Intestinal parasitic infections in schoolchildren in different settings of Côte d'Ivoire: effect of diagnostic approach and implications for control. Parasit Vectors 5: 135.
2. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, et al. (2006) Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 367: 1521–1532.
3. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027.
4. Stephenson LS, (1994) Helminth parasites, a major factor in malnutrition. World Health Forum 15: 169–172.
5. Vecchiato NL (1997) Digestive worms: ethnomedical approaches to intestinal parasitism in southern Ethiopia. In Inhorn MC, Brown PJ, editors. The Anthropology of Infectious Disease: international health perspectives. Amsterdam: Gorden and Breach publishers. pp. 241–266.
6. Wiwanitkit V, (2006) Intestinal parasite infestation in HIV infected patients. Curr HIV Res 4: 87–96.
7. Keiser J, Utzinger J, (2010) The drugs we have and the drugs we need against major helminth infections. Adv Parasitol 73: 197–230.
8. WHO (2006) Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization.
9. Minvielle MC, Basualdo JA, Ciarmela ML, Niedfeld G, (1999) Anthelmintic efficacy of tinidazole against the progression of Toxocara canis larvae to the brain in mice. Parasitol Res 85: 830–832.
10. Keiser J, Utzinger J, (2008) Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299: 1937–1948.
11. Olsen A, (2003) Experience with school-based interventions against soil-transmitted helminths and extension of coverage to non-enrolled children. Acta Trop 86: 255–266.
12. Heyman ML, Williams RL, (2011) Ensuring global access to quality medicines: Role of the US pharmacopeia. J Pharm Sci 100: 1280–1287.
13. WHO (2012) Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. Geneva: World Health Organization.
14. Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, et al. (2008) Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 13: 1062–72.
15. Juillet Y, (2008) Update on counterfeit drugs: a growing risk for public health. Bull Acad Natl Med 192: 1423–1434.
16. Nsimba SE, (2008) Problems associated with substandard and counterfeit drugs in developing countries: A review article on global implications of counterfeit drugs in the era of anti-retroviral (ARVS) drugs in a free market economy. East Afr J Public Health 5: 205–210.
17. Ten Ham M, (2003) Health risks of counterfeit pharmaceuticals. Drug Safety 26: 991–997.
18. WHO (2011) Survey of the quality of selected anti-malarial medicines circulating in six countries of sub-Saharan Africa. Geneva: World Health Organization.
19. WHO (1999) Specifications for prepackaging anti-malarial medicines. Geneva: World Health Organization.
20. Nasr N (2004) Risk Based CMC Review Paradigm. Presentation at FDA Advisory Committee for Pharmaceutical Science Meeting, July 20–21. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4052S1_10_Nasr.ppt. Accessed 21 January 2013.
21. Chakraborty AK, Borah GK (1989) An application of the concept of desirability functions in evaluating erection quality. Qual Eng: 443–452.
22. Derringer GC (1994) A balancing act: optimizing a product's properties. Quality Progress, 51–58. American Society for Quality.
23. Newton PN, Lee SJ, Goodman C, Fernández FM, Yeung S, et al. (2009) Guidelines for field surveys of the quality of medicines: A proposal. PLoS Med 6: e1000052.
24. Jung H, Medina L, Garcia L, Fuentes I, Esparza MR, (1998) Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol 50: 43–48.
25. Subramanian S, Singireddy A, Krishnamoorthy K, Rajappan M, (2012) Nanosponges: A novel class of drug delivery system – review. J Pharm Pharmaceut Sci 15: 103–111.
26. Dressman JB, Reppas C, (2000) In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J of Pharm Sci 11: S73–S80.
27. Harry MJ, Mann PS, De Hodgins OC, Hulbert RL, Lacke CJ, (2010) Practitioner's guide to statistics and lean six sigma for process improvements. Wiley
28. International Conference on Harmonization, editor (2006) Guidance for Industry Q9-Quality Risk Management.
29. Braglia M, (2000) MAFMA: Multi-attribute failure mode analysis. Int J Qual Reliab Manage 17: 1017–1033.
30. Chang KH, (2009) Evaluate the orderings of risk for failure problems using a more general RPN methodology. Microelectron Reliab 49: 1586–1596.
31. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, et al. (2001) Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357: 1933–1936.
32. Monteiro A, Wanyangu S, Kariuki D, Bain R, Jackson F, et al. (1998) Pharmaceutical quality of anthelmintics sold in Kenya. Vet Rec 142: 396–398.
33. Kahsay G, G/Egziabher A, (2010) Quality Assessment of the Commonly Prescribed Antimicrobial Drug, Ciprofloxacin Tablets, Marketed in Tigray, Ethiopia. Memona Ethiop J Sci 2: 93–107.
34. Suleman S, Debella A, (2007) Comparative evaluation of invitro characteristics of tablets of the commonly prescribed antiepileptic drugs: carbamazepine and phenobarbitone. Ethiop J Health Sci 17: 147–153.
35. Wu FC, (2005) Optimization of correlated multiple quality characteristics using desirability function. Qual Engng 17: 119–126.
36. Fogliatto FS, (2008) Multiresponse optimization of products with functional quality characteristics. Qual Reliab Engng Int 24: 927–939.
37. Bikbulatov ES, Stepanova IE, (2011) Harrington's Desirability Function for Natural Water Quality Assessment. Russ J Gen Chem 81: 2694–2704.
38. International Conference on Harmonization, editor (2006) Guidance for Industry Q8-Pharmaceutical Development.
39. Attaran A, Barry D, Bashir S, Bate R, Benton D, Chauvin J, et al. (2012) How to achieve international action on falsified and substandard medicines. BMJ 345: e7381.
40. Baert B, De Spiegeleer B, (2010) Quality analytics of internet pharmaceuticals. Anal Bioanal Chem 398: 125–136.
41. WHO (2009) Survey of the quality of selected anti-malarial medicines circulating in Madagascar, Senegal, and Uganda. Geneva: World Health Organization.
42. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, et al. (2009) Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 8: 22.
43. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME, (2007) Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 60: 214–236.
44. Khan MH, Okumura J, Sovannarith T, Nivanna N, Akazawa M, et al. (2010) Prevalence of counterfeit anthelminthic medicines: a cross-sectional survey in Cambodia. Trop Med Int Health 15: 639–644.
45. Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, et al. (2012) Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis 12: 888–896.
46. Martins JM, Farinha A, (1998) Uniformity of dosage units: comparative study of methods and specifications between Eur. Pharm. 3rd and USP 23. J Pharm Sci Biomed Anal 18: 487–495.
47. Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, et al. (2011) Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and taenia sppecies: a randomized controlled trial. PLoS One 6: e25003.
48. Dickinson PA, Lee WW, Stitt PW, Townsend AI, Smart JP, (2008) Clinical relevance of disssolution testing in quality by design. AAPS J 10: 280–290.
49. Chung MS, Joo KH, Quan FS, Kwon HS, Cho SW, (2001) Efficacy of flubendazole and albendazole against Trichinella spiralis in mice. Parasite 8: S195–S198.
50. Siriyasatien P, Yingyourd P, Nuchprayoon S, (2003) Efficacy of albendazole against early and late stage of Trichinella spiralis infection in mice. J Med Assoc Thai 86: S257–S262.
51. Pranzo MB, Cruickshank D, Coruzzi M, Caura MR, Bettini R, (2010) Enantiotropically related albendazole polymorphs. J Pharm Sci 99: 3731–3742.
52. García-Rodrigueza JJ, de la Torre-Iglesias PM, Vegas-Sáncheza MC, Torrado-Duránb S, Bolás-Fernándeza F, (2011) Changed crystallinity of mebendazole solid dispersion: improved anthelmintic activity. Int J Pharmaceutics 403: 23–28.
53. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ, (2004) The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharmaceutics 272: 29–36.
54. Honorato SB, Farfan S, Viana A, Filho JM, Camarão GC, (2012) Polymorphism evaluation in generic tablets containing mebendazole by dissolution tests. J Braz Chem Sos 23: 220–227.
55. Brits M, Liebenberg W, De Villers MM, (2010) Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole. J Pharm Sci 99: 1138–1151.
56. Borka L, Haleblian JK, (1990) Crystal polymorphism of pharmaceuticals. Acta Pharm Jugosl 40: 71–94.
57. WHO (2002) Strategy development and monitoring for parasitic diseases and vector control (PVC), control, prevention and eradication (CPE) programme on communicable diseases (CDS). Geneva: World Health Organization.
58. Dayan AD, (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86: 141–159.
59. FMHACA (2010) Standard Treatment Guidelines for General Hospitals. Drug Adminstration and Control Authority, Addis Ababa, Ethiopia.
60. Vercruysse J, Albonico M, Behnke JM, Kotze AC, Prichard RK, et al. (2011) Is anthelmintic resistance a concern for the control of human soil-transmitted helminths? Int J Parasitol: Drugs and Drug Resistance 1: 14–27.
61. Hung GQ, Nie M, Mark KL, (1999) Web-based failure mode and effect analysis. Comput Ind Eng 37: 177–180.
62. United States MIL-STD 1629-A (1998) Procedure for performing a failure mode, effects and criticality analysis. Department of Defense, Washington, DC.
63. Safa F, Hadjmohammadi MR, (2005) Simultaneous optimization of the resolution and analysis time in micellar liquid chromatography of phenyl thiohydantoin amino acids using Derringer's desirability function. J Chromatogr A 1078: 42–50.
64. Sivakumar T, Manavalan R, Valliappan K, (2007) Global optimization using Derringer's desirability function: Enantioselective determination of ketoprofen in formulations and in biological matrices. Acta Chromatogr 19: 29–47.
65. Van Dorpe S, Adriaens A, Vermeire S, Polis I, Peremans K, De Spiegeleer B, (2011) Desirability function combining metabolic stability and functionality of peptides. J Pept Sci 17: 398–404.
66. D'Hondt M, Verbeke F, Stalmans S, Gevaert B, Wynendaele E, et al. (2013) Derringer desirability and kinetic plot LC-column comparison approach for MS-compatible lipopeptide analysis. J Pharm Anal http://dx.doi.org/10.1016/j.jpha.2013.09.001.
67. Segall MD (2009) Multi-Parameter Optimization: Identifying high quality compounds with a balance of properties. Optibrium Ltd, Cambridge, UK.